ReviewCancers2021
Advances in Immunotherapy for Adult Glioblastoma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Efficacy and survival outcomes of bevacizumab plus minocycline for glioblastoma.American journal of translational research · 2025Article
- Bioluminescent Imaging of Patient-Derived Brain Tumors in Live Mice.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Research Progress with Atractylone as an Antitumor Agent.Molecules (Basel, Switzerland) · 2024Review
- Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy.Molecular biology reports · 2024Review
- Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.Nature medicine · 2024Article
- Neuroinflammation in Glioblastoma: Progress and Perspectives.Brain sciences · 2024Review
- Complementary roles of EP2 and EP4 receptors in malignant glioma.British journal of pharmacology · 2023Article
- Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023Review
- Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma.Frontiers in immunology · 2023Review
- In Vitro Cytotoxic Effects and Mechanisms of Action of Eleutherine Isolated fromMolecules (Basel, Switzerland) · 2022Article
- Exploring the prognostic value of HK3 and its association with immune infiltration in glioblastoma multiforme.Frontiers in genetics · 2022Article
- Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors.Frontiers in immunology · 2022Article
- Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.OncoTargets and therapy · 2022Review
- Novel Treatment Strategies for Glioblastoma-A Summary.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we summarize recent clinical and preclinical efforts to evaluate vaccination strategies, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells. Although these modalities have shown long-term tumor regression in subsets of treated patients, the underlying biology that may predict efficacy and inform therapy development is being actively investigated. Common to all therapeutic modalities are fundamental mechanisms of therapy evasion by tumor cells, including immense intratumoral heterogeneity, suppression of the tumor immune microenvironment and low mutational burden. These insights have led efforts to design rational combinatorial therapies that can reignite the anti-tumor immune response, effectively and specifically target tumor cells and reliably decrease tumor burden for GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.